ABUS Earnings Prediction
The chart below shows how ABUS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ABUS sees a +6.70% change in stock price 10 days leading up to the earnings, and a -0.70% change 10 days following the report. On the earnings day itself, the stock moves by -1.23%. This data can give you a slight idea of what to expect for the next quarter's release.
ABUS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.34M
-71.25%
-22.42%
Gross Margin
--
--
--
Operating Margin
-1304.78%
184.63%
5.37%
Net Margin
-1472.52%
241.18%
28.39%
EPS
-0.10
-16.67%
-9.09%
No Data Available
ABUS Earnings Analysis
Arbutus Biopharma Corporation Common Stock Corporation (ABUS.O) Earnings Conference Call
Positive
Solid Financial Foundation: 1. Strong Cash Position: Arbutus Biopharma ended Q3 2024 with approximately $131 million in cash, cash equivalents, and marketable securities, providing a solid financial foundation to support operations into Q4 2026.
Surface Antigen Loss Rates: 2. High Surface Antigen Loss Rates: In the IM-PROVE I trial, 33% of patients achieved sustained surface antigen loss after treatment, with 67% of patients with baseline surface antigen less than 1,000 IU/mL maintaining this loss 24 weeks post-treatment, indicating promising efficacy.
IM-PROVE II Trial Success: 3. Successful IM-PROVE II Trial Results: The IM-PROVE II trial showed that 95% of patients achieved surface antigen levels below 100 IU/mL after treatment with imdusiran, demonstrating the treatment's effectiveness in lowering viral markers.
Key Opinion Leader Support: 4. Positive Feedback from Key Opinion Leaders: The company has received encouraging feedback on their clinical data from key opinion leaders in the HBV field, suggesting strong interest and support for their ongoing research.
AB-101 Trial Success: 5. Advancement of AB-101: The AB-101 trial has shown that all subjects in the 25-milligram cohort demonstrated PD-L1 receptor occupancy greater than 70%, indicating effective interaction with the intended target and a favorable safety profile.
Negative
Cash Burn Analysis: 1. Cash Burn Concerns: Arbutus reported a cash burn of $54.5 million in the first half of 2024, with expectations for the full year cash burn to range from $63 million to $67 million, indicating significant operational expenditures without corresponding revenue growth.
Cash Position Stagnation: 2. Stagnant Cash Position: The company ended Q3 2024 with approximately $131 million in cash and equivalents, a slight decrease from $132 million at the end of 2023, suggesting limited financial progress despite cash inflows from share issuances earlier in the year.
Share Issuance Status: 3. No Share Issuance in Q3: Arbutus did not issue any common shares under its at-the-market offering program during Q3 2024, which may limit its ability to raise additional funds in a timely manner.
Phase IIb Trial Delays: 4. Delayed Phase IIb Trial: There is no clear timeline for the initiation of the Phase IIb clinical trial for imdusiran, indicating potential delays in advancing their key therapeutic candidate to the next stage of development.
Litigation Impact on Strategy: 5. Litigation Uncertainty: The trial date for the Moderna lawsuit is set for September 2025, and the outcome of the ongoing litigation with Pfizer/BioNTech remains uncertain, which could impact the company's strategic direction and financial stability.
ABUS FAQs
How does ABUS typically perform around its earnings report dates?
Is Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ABUS Earning Call Sentiment
Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript
ABUS.O
1.45%Positive
The earnings call summary indicates a stable financial position with a sufficient cash runway and ongoing clinical trials. However, concerns arise from management's vague responses in the Q&A, regulatory risks, competitive pressures, and ongoing litigation. Despite a strong cash position and strategic focus, these uncertainties likely balance out any potential positive sentiment, leading to a neutral outlook for the stock price over the next two weeks.
